Health Care & Life Sciences » Medical Equipment & Supplies | Second Sight Medical Products Inc.

Second Sight Medical Products Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
22,968.90
35,201.20
20,018.00
33,179.00
28,516.00
35,094
Depreciation, Depletion & Amortization
315.80
279.20
335.00
432.00
457.00
435
Other Funds
-
-
124.00
-
-
4,424
Funds from Operations
16,869.60
18,690.10
16,672.00
24,120.00
27,261.00
30,235
Changes in Working Capital
720.80
1,597.80
3,877.00
950.00
3,314.00
425
Net Operating Cash Flow
17,590.40
17,092.30
20,549.00
25,070.00
23,947.00
29,810
Capital Expenditures
246.00
560.40
762.00
490.00
265.00
Purchase/Sale of Investments
4,301.60
25,387.90
18,279.00
5,378.00
3,106.00
Net Investing Cash Flow
4,547.60
25,948.30
17,517.00
4,888.00
2,841.00
Issuance/Reduction of Debt, Net
19,465.50
-
-
-
-
Net Financing Cash Flow
21,974.60
43,804.00
2,759.00
20,452.00
21,168.00
Net Change in Cash
245.80
556.80
380.00
300.00
65.00
Free Cash Flow
17,836.40
17,652.70
21,311.00
25,560.00
24,212.00
Change in Capital Stock
2,509.10
43,804.00
2,883.00
20,452.00
21,168.00
Exchange Rate Effect
82.40
206.50
107.00
30.00
3.00

About Second Sight Medical Products

View Profile
Address
12744 San Fernando Road
Sylmar California 91342
United States
Employees -
Website http://www.secondsight.com
Updated 07/08/2019
Second Sight Medical Products, Inc. develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The firm's system works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.